The present invention provides compounds of formula I, 1
and pharmaceutically acceptable salts thereof.
The formula I compounds inhibit the tyrosine kinase activity of growth
factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful
as anti-cancer agents. The formula I compounds are also useful for the
treatment of other diseases associated with signal transduction pathways
operating through growth factor receptors.
